These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 31365818)

  • 21. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
    Liu J; Cao L; Wu J
    Front Public Health; 2022; 10():987408. PubMed ID: 36187655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
    Al-Dhaher Z; Kapoor S; Saito E; Krakower S; David L; Ake T; Kane JM; Correll CU; Carbon M
    J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):458-70. PubMed ID: 27093218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
    Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
    BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.
    Ennis ZN; Damkier P
    Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):315-20. PubMed ID: 25536446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delirium in hospitalized patients: Risks and benefits of antipsychotics.
    Thom RP; Mock CK; Teslyar P
    Cleve Clin J Med; 2017 Aug; 84(8):616-622. PubMed ID: 28806160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
    Carbon M; Kapoor S; Sheridan E; Al-Jadiri A; Azzo S; Sarkaria T; Kane JM; Saito E; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):718-727.e3. PubMed ID: 26299293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.
    Koch MT; Carlson HE; Kazimi MM; Correll CU
    J Am Acad Child Adolesc Psychiatry; 2023 Sep; 62(9):1021-1050. PubMed ID: 36931560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
    Yu CL; Carvalho AF; Thompson T; Tsai TC; Tseng PT; Hsu CW; Hsu TW; Liang CS
    BMJ Ment Health; 2023 Feb; 26(1):. PubMed ID: 36789916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia.
    Hattori S; Kishida I; Suda A; Miyauchi M; Shiraishi Y; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Taguri M; Hirayasu Y
    Schizophr Res; 2018 Mar; 193():134-138. PubMed ID: 28709776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Narrative review of the advances in the pharmacotherapeutic management of juvenile-onset schizophrenia.
    Crump CJ; Good ME; Abuelazm H; El-Mallakh RS
    Expert Opin Pharmacother; 2023 Jun; 24(9):1039-1052. PubMed ID: 37102321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses.
    Poulos J; Normand ST; Zelevinsky K; Newcomer JW; Agniel D; Abing HK; Horvitz-Lennon M
    Psychol Med; 2023 Dec; 53(16):7677-7684. PubMed ID: 37753625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.
    Restelli U; García-Goñi M; Lew-Starowicz M; Mierzejewski P; Silvola S; Mayoral-van Son J; Croce D; Rocca P; Crespo-Facorro B
    Clin Drug Investig; 2020 Sep; 40(9):861-871. PubMed ID: 32648201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.